Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
FDA Oncology Update
FDA Oncology Update
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Jerm Day-Storms, PhD, MWC
Read More
FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Read More
FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Read More
FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Read More
FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Read More
FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Read More
FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
Read More
FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
Read More
FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
Read More
FDA Oncology Update
Braftovi Plus Mektovi Now FDA Approved for Treatment of Metastatic Non–Small Cell Lung Cancer With BRAF Mutation
Read More
1
2
3
4
Page 1 of 26
Results 1 - 10 of 253